Advanced in Febrile Neutropenia

Dimitrios Pectasides

Athens, ESYE31, GR 
Advanced in Febrile Neutropenia
Athens, ESYE31, GR 
OverviewLocationsClinical Research

Overview

Dimitrios Pectasides practices in Athens, Greece. Mr. Pectasides is rated as an Advanced expert by MediFind in the treatment of Febrile Neutropenia. His top areas of expertise are Breast Cancer, Colorectal Cancer, Febrile Neutropenia, and Nonalcoholic Steatohepatitis (NASH).

His clinical research consists of co-authoring 260 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Febrile Neutropenia.

Gender
Male

Locations

Athens, ESYE31, Greece
Other Locations
Piraeus, ESYE31, Greece
Thessaloniki, ESYE12, Greece

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Phase II Multicenter Single-arm Study Evaluating the Safety and Efficacy of Everolimus as a First-line Treatment in Newly-diagnosed Patients With Advanced GI Neuroendocrine Tumors.
Phase II Multicenter Single-arm Study Evaluating the Safety and Efficacy of Everolimus as a First-line Treatment in Newly-diagnosed Patients With Advanced GI Neuroendocrine Tumors.
Enrollment Status: Terminated
Publish Date: September 03, 2019
Intervention Type: Drug
Study Phase: Phase 2
Phase II Single-arm Study of First Line Treatment With Gemcitabine and Pazopanib in Patients With Inoperable Locally Advanced or Metastatic Biliary Tree Cancer (Cholangiocarcinoma or Gallbladder Carcinoma)
Phase II Single-arm Study of First Line Treatment With Gemcitabine and Pazopanib in Patients With Inoperable Locally Advanced or Metastatic Biliary Tree Cancer (Cholangiocarcinoma or Gallbladder Carcinoma)
Enrollment Status: Terminated
Publish Date: November 07, 2018
Intervention Type: Drug
Study Phase: Phase 2
Phase II Study of Cabazitaxel as 2nd Line Treatment in Patients With HER-2 Negative Metastatic Breast Cancer Previously Treated With Taxanes
Phase II Study of Cabazitaxel as 2nd Line Treatment in Patients With HER-2 Negative Metastatic Breast Cancer Previously Treated With Taxanes
Enrollment Status: Completed
Publish Date: August 01, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 2 Less Clinical Trials

260 Total Publications

Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: A hellenic cooperative oncology group observational study (HE 10/10) with concurrent investigation of significance of tumor infiltrating lymphocytes.
Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: A hellenic cooperative oncology group observational study (HE 10/10) with concurrent investigation of significance of tumor infiltrating lymphocytes.
Journal: Breast (Edinburgh, Scotland)
Published: October 26, 2023

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Pectasides's expertise for a condition
ConditionClose
    View All 19 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile